Irritable Bowel Syndrome News and Research RSS Feed - Irritable Bowel Syndrome News and Research

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine, often causing bouts of cramping, abdominal pain, bloating, diarrhea and constipation.

IBS is not curable but, in most cases, people learn to live with and control the condition by managing diet, lifestyle and stress levels. Medications to treat diarrhea, pain killers or drugs that relieve painful bowel spasms may also be used.

The cause of IBS is not yet clear but it is linked to changes in the way food is moved through the bowel. In healthy people, layers of muscle lining the intestinal wall contract and relax in a coordinated manner to move food from the stomach, through the colon and into the rectum. When an individual has IBS, however, the contractions are unusually strong and food is passed through the intestine too quickly which leads to diarrhea and a build up of gas.

Triggers for IBS range from pressure on the intestines to certain foods such as chocolate or carbonated drinks, hormonal changes such as during the menstrual cycle and emotional changes such as an increase in stress.

IBS can be painful and debilitating if not treated appropriately, negatively impacting on a person’s quality of life. However, with appropriate treatment individuals with IBS should be able to live a full and active life.

Painkillers may not offer relief to people suffering from irritable bowel syndrome

University of Adelaide researchers have discovered that the immune system is defective in people suffering from irritable bowel syndrome, which is a major reason why sufferers have ongoing issues with pain. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN for patients with epithelioid malignant pleural mesothelioma (MPM). [More]
New disposable device may help doctors to monitor post-operative ileus

New disposable device may help doctors to monitor post-operative ileus

A disposal, plastic listening device that attaches to the abdomen may help doctors definitively determine which post-operative patients should be fed and which should not, an invention that may improve outcomes, decrease healthcare costs and shorten hospital stays, according to a UCLA study. [More]
New noninvasive method could lead to better diagnosis, treatment of gut diseases

New noninvasive method could lead to better diagnosis, treatment of gut diseases

A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time could lead to better diagnosis and treatment of gut diseases. [More]
Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Independent testing organization confirms VSL#3 formulation as probiotic product

Independent testing organization confirms VSL#3 formulation as probiotic product

Probiotics have gained in popularity in recent years and consumers now have many to choose from. However, only 14 of 19 successfully tested through Consumer Lab's quality certification program probiotics. [More]
Researchers develop new "nanojuice" to help doctors better identify human gut

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way. [More]
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract. [More]
Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines are generally being defined as medicines which are non-mainstream medicines and are mostly given together with conventional medicines. [More]
Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients. [More]
Squatty Potty toilet stool improves severity of constipation symptoms

Squatty Potty toilet stool improves severity of constipation symptoms

When used as a treatment, the original Squatty Potty (www.squattypotty.com) toilet stool significantly improves the severity of constipation symptoms within one month of use among 84 percent of the participants of a recently released scientific study. [More]
Cell Science Systems launches new blood test profile for GI disorders

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. [More]
University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded with the honorary degree, Doctor of Science Honoris Causa, from his alma mater, the University of Missouri - St. Louis, at a commencement ceremony this Saturday, May 17, 2014. [More]
Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures. [More]
Vibrating oral capsule for chronic constipation shows positive results

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW). [More]